Pharmaceutical

Risk adjusted net present value: What is the current valuation of Merck’s MK-1084?

MK-1084 is a small molecule commercialized by Merck, with a leading Phase I program in Metastatic Colorectal Cancer.

Apr 17, 2024 - 00:00
MK-1084 is a small molecule commercialized by Merck, with a leading Phase I program in Metastatic Colorectal Cancer.
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of AstraZeneca’s ...

Next Article

Risk adjusted net present value: What is the current valuation of AbbVie’s ABBV-...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Formation Bio secures $372m funds for AI-driven drug platform

Formation Bio secures $372m funds for AI-driven drug pl...

Jun 28, 2024

Drugmakers push back on a clever tactic employers use to avoid paying for specialty medicines

Drugmakers push back on a clever tactic employers use t...

Mar 22, 2023

Vast sequencing project begins to unlock human genome’s secrets — by deciphering other mammals’ DNA

Vast sequencing project begins to unlock human genome’s...

Apr 27, 2023